Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind non-inferiority trial of GSK3511294 vs mepolizumab or benralizumab in severe eosinophilic asthma
jRCT2031200414Completed
- Sponsor
- GSK
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of depemokimab in eosinophilic asthma (EA) (3 arms), sponsored by GSK. Primary endpoint: Annualized rate of clinically significant exacerbations over 52 weeks. Started Mar 2021; status: completed.
02
Drugs
depemokimab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on jRCT2031200414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200414.